RecruitingNCT07196930

Valvular Heart Disease in Women Registry


Sponsor

Valvular Heart Disease in Women Registry

Enrollment

800 participants

Start Date

Apr 1, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Valvular heart disease (VHD) is a major global health issue. Untreated rheumatic heart disease persists in many regions, preventable with timely care. Higher-income countries face rising calcific valve disease from aging, worsened by VHD complications, like infective endocarditis, resulting in higher morbidity/mortality. Gender disparities in VHD remains understudied, despite inequalities in risks, diagnosis, and treatment. Prevalence varies by gender, but uneven diagnostics and therapies obscure realities. This registry will examine gender disparities from hospital admission to first outpatient follow-up, recruiting both men and women to investigate and report the study objectives.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Adult patients with diagnosis of any VHD according to the current ESC guidelines.
  • Admission to the VHD-W Registry collaborating center.

Exclusion Criteria2

  • Age less than 18 years old.
  • Inability to provide informed consent per local institutional and regulatory requirements.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(2)

Aswan Heart Centre

Aswān, Egypt

University of Lisbon

Lisbon, Portugal

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07196930


Related Trials